Kim L. O'Neill - Wikipedia

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)

This biography of a living person needs additional citations for verification. Please help by adding reliable sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libelous.
Find sources: "Kim L. O'Neill" – news · newspapers · books · scholar · JSTOR (July 2012) (Learn how and when to remove this message)

This article includes a list of general references, but it lacks sufficient corresponding inline citations. Please help to improve this article by introducing more precise citations. (July 2012) (Learn how and when to remove this message)

The topic of this article may not meet Wikipedia's notability guideline for academics. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.
Find sources: "Kim L. O'Neill" – news · newspapers · books · scholar · JSTOR (July 2012) (Learn how and when to remove this message)

(Learn how and when to remove this message)

Kim L. O'Neill is the developer of a monoclonal antibody that allows for the accurate, cheap and easy detection of cancer.

O'Neill has a B.Sc. degree from New University of Ulster and a Ph.D. from the University of Ulster. He is a full professor of microbiology at Brigham Young University. In 1998 research by O'Neill suggested a link between caffeine and the formation of some cancers.^[1] O'Neill has served as associate director of BYU's cancer research center.

O'Neill is also a convert to the Church of Jesus Christ of Latter-day Saints, having joined the church in Ireland.